Iohexol + Iodixanol + Iopromide + Ioversol
ApprovedWithdrawn 0 views this week 0 watching💤 Quiet
Interest: 32/100
32
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Hypothyroidism
Conditions
Hypothyroidism
Trial Timeline
Mar 1, 2022 → Feb 1, 2025
NCT ID
NCT03631771About Iohexol + Iodixanol + Iopromide + Ioversol
Iohexol + Iodixanol + Iopromide + Ioversol is a approved stage product being developed by Bayer for Hypothyroidism. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT03631771. Target conditions include Hypothyroidism.
What happened to similar drugs?
1 of 1 similar drugs in Hypothyroidism were approved
Approved (1) Terminated (1) Active (0)
Hype Score Breakdown
Clinical
20
Activity
0
Company
12
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03631771 | Approved | Withdrawn |
Competing Products
5 competing products in Hypothyroidism
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Growth hormone + Growth hormone treatment and puberty | Eli Lilly | Approved | 35 |
| Armour Thyroid + Levothyroxine | AbbVie | Phase 2/3 | 45 |
| iodinated contrast agents | Bayer | Pre-clinical | 23 |
| Iodinated contrast agents | Bayer | Pre-clinical | 23 |
| levothyroxine sodium | Xeris Pharmaceuticals | Phase 2 | 29 |